MENLO PARK, Calif., Dec. 20, 2010 /PRNewswire/ -- Leader Ventures, an investment firm offering blended debt and equity financing, today announced equipment financing to Carmot Therapeutics Inc., an innovative drug discovery company.
Chemotype Evolution, Carmot's proprietary drug-discovery platform invented by Carmot co-founders Stig K. Hansen and Daniel A. Erlanson while at Sunesis, is being used to identify promising drug candidates in a broad range of therapeutic areas.
"Leader's flexibility and understanding of our needs has been a tremendous source of support for Carmot, not only financially," said Stig K. Hansen, CEO at Carmot Therapeutics Inc. "We're looking forward to continuing to work with Leader Ventures as we grow and lead innovation in drug discovery."
"The leadership team is what first attracted us to Carmot," said Brian Best, managing director at Leader Ventures. "We then learned about the Chemotype Evolution technology platform making rapid identification of compounds for a wide variety of challenging disease targets a reality."
About Carmot Inc.Carmot Therapeutics was founded by Drs. Hansen and Erlanson in 2008 with the goal of commercializing and further developing Chemotype Evolution. Carmot has licensed the technology and fragment libraries from Sunesis, and Carmot is in the process of further expanding the capabilities of Chemotype Evolution. Chemotype Evolution is a patent pending technology that was invented by Drs. Stig K. Hansen and Daniel A. Erlanson while they were working at Sunesis Pharmaceuticals.
About Leader Ventures: Leader Ventures is a private investment firm providing blended debt and equity financing to a diversified portfolio of private and public companies. With offices in San Francisco and Menlo Park, the firm invests primarily in the U.S. and employs a variety of loan plus equity structures to invest in companies at different developmental stages, across diverse industry segments. For more information, please visit www.leaderventures.com.Leader Ventures PR Contact:Paulien Ruijssenaars650.email@example.com
|SOURCE Leader Ventures|
Copyright©2010 PR Newswire.
All rights reserved